• Product name
    Anti-CXCL7/PBP antibody [500-M33]
    See all CXCL7/PBP primary antibodies
  • Description
    Mouse monoclonal [500-M33] to CXCL7/PBP
  • Host species
  • Tested applications
    Suitable for: ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant full length protein corresponding to CXCL7/PBP.

  • Positive control
    • Recombinant Human CXCL7/PBP protein (ab9556) can be used as a positive control in WB.
  • General notes

    Previously labelled as CXCL7. 



Our Abpromise guarantee covers the use of ab9555 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    ELISA:This antibody can be used at a concentration of 1-2µg/ml, as a capture antibody in conjunction with a compatible secondary reagent to yield satisfactory results in a sandwich ELISA (using 100µg/well antibody solution).
  • Target

    • Function
      LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.
    • Sequence similarities
      Belongs to the intercrine alpha (chemokine CxC) family.
    • Post-translational
      Proteolytic removal of residues 1-9 produces the active peptide connective tissue-activating peptide III (CTAP-III) (low-affinity platelet factor IV (LA-PF4)).
      Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along with platelet factor 4 and platelet-derived growth factor.
      NAP-2(1-66) is produced by proteolytical processing, probably after secretion by leukocytes other than neutrophils.
      NAP-2(73) and NAP-2(74) seem not be produced by proteolytical processing of secreted precursors but are released in an active form from platelets.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • B TG1 antibody
      • Beta TG antibody
      • Beta thromboglobulin antibody
      • Beta-TG antibody
      • C-X-C motif chemokine 7 antibody
      • Chemokine (C X C motif) ligand 7 antibody
      • Connective tissue activating peptide III antibody
      • CTAP 3 antibody
      • CTAP III antibody
      • CTAP-III antibody
      • CTAP-III(1-81) antibody
      • CTAP3 antibody
      • CTAPIII antibody
      • CXC chemokine ligand 7 antibody
      • CXCL 7 antibody
      • CXCL7 antibody
      • CXCL7_HUMAN antibody
      • LA PF 4 antibody
      • LA-PF4 antibody
      • LDGF antibody
      • Leukocyte derived growth factor antibody
      • Leukocyte-derived growth factor antibody
      • Low-affinity platelet factor IV antibody
      • Macrophage-derived growth factor antibody
      • MDGF antibody
      • NAP 2 antibody
      • NAP-2 antibody
      • NAP-2(1-63) antibody
      • NAP-2(1-66) antibody
      • NAP-2(73) antibody
      • NAP-2(74) antibody
      • Neutrophil activating peptide 2 antibody
      • Neutrophil-activating peptide 2(1-63) antibody
      • PBP antibody
      • Platelet basic protein antibody
      • PPBP antibody
      • Pro platelet basic protein (chemokine (C-X-C motif) ligand 7) antibody
      • Pro platelet basic protein antibody
      • SCYB7 antibody
      • Small inducible cytokine subfamily B member 7 antibody
      • Small-inducible cytokine B7 antibody
      • TC1 antibody
      • TC2 antibody
      • TGB antibody
      • TGB1 antibody
      • THBGB antibody
      • THBGB1 antibody
      • Thrombocidin 1 antibody
      • Thrombocidin 2 antibody
      • Thromboglobulin, beta-1 antibody
      see all


    This product has been referenced in:
    • Wadi S  et al. hGBP-1 Expression Predicts Shorter Progression-Free Survival in Ovarian Cancers, While Contributing to Paclitaxel Resistance. J Cancer Ther 7:994-1007 (2016). Read more (PubMed: 28090373) »
    See 1 Publication for this product

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A


    Thank you for your phone call. As discussed over the phone, I have arranged for free of charge replacements to be sent to you. The items are on order# 96192 and you should receive these by Tuesday of next week. You will receive email confirmations regarding shipping to keep you updated. If you have any additional questions or concerns, please let me know.

    Read More


    Thank you for your enquiry over the phone yesterday. I have an answer from the source of the antibody: For both our monoclonal and polyclonal anti-Human NAP2 (ab9555 and ab9554), recombinant Human NAP-2 (ab9556) (70a.a form) was used as the immunizing antigen which corresponds to position 59-128 from the published sequence found on expasy. Here is the link for NAP2 on the expasy site: http://ca.expasy.org/cgi-bin/niceprot.pl?P02775 I hope this helps, please do not hesitate to contact me if you need further information,

    Read More


    Sign up